Pirtobrutinib (LOXO-305), a next generation highly selective non-covalent Bruton's Tyrosine Kinase inhibitor in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the Phase 1/2 BRUIN study

Toby Eyre, John M Pagel, Catherine C Coombs, Nirav N Shah, Nicole Lamanna, Ewa Lech-Maranda, Jennifer Woyach, William G Wierda, Chan Y Cheah, Lindsey Roeker, Manish R Patel, Bita Fakhri, Minal A Barve, Constantine S Tam, David Lewis, James N Gerson, Alvaro Alencar, Justin Taylor, Omar Abedel-Wahab, Paolo Ghia Show all